Silodosin Recordati from Recordati S.p.A. - focused 8 mg capsule for BPH symptom relief

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-22, 10:56. Details in the imprint.

Silodosin Recordati 8 mg hard capsules sit in a white-and-blue carton that many urologists now recognise at a glance on their sample shelves. For patients, the small capsule aims to turn nightly bathroom trips into quieter, longer stretches of sleep. It is a focused, prescription treatment rather than a lifestyle pill.

What Silodosin Recordati does

Silodosin Recordati is an ?1A-adrenoceptor antagonist indicated for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in adult men, including elderly patients. It uses the active substance silodosin in an 8 mg once-daily dose, usually taken with food. According to the official summary of product characteristics, the selectivity for ?1A receptors in prostatic tissue is designed to relax smooth muscle in the prostate and bladder neck, easing urine flow and reducing urgency. The European Medicines Agency referral documentation describes the pharmacological profile and indications in detail.

Urologist Dr. Marco Rossi from Milan describes a typical patient as a man in his late sixties who feels a constant pressure to find a toilet, especially in the evening. When the treatment works, Rossi says the first thing many men report is a calmer night with fewer awakenings and less "stop-and-go" at the toilet bowl. That immediate sensory relief often matters more to them than any number on a flow chart.

Dose, tolerability and daily use

The standard regimen for Silodosin Recordati in Europe is one 8 mg capsule taken once daily, preferably with food at the same time each day, which helps keep plasma levels steady. In many countries, the product is available in blister strips inside a cardboard carton, with packs often containing 30 hard capsules. The capsule is swallowed whole with water and should not be opened or chewed, a detail that pharmacists usually stress to older patients who already take multiple tablets. A UK summary of product characteristics gives the dosing and packaging as well as precautions.

Recordati literature points out that the ?1A selectivity can reduce blood-pressure-related side effects compared with less selective ?-blockers, although dizziness and orthostatic hypotension remain known risks, particularly at treatment initiation. Patients are advised to stand up slowly from sitting or lying positions, and ophthalmologists should be informed about silodosin use because of the risk of intraoperative floppy iris syndrome during cataract surgery. The Italian medicines agency information for Silodosin Recordati highlights these warnings and lists common adverse reactions, including altered ejaculation.

How it fits in Recordati’s portfolio

CEO Andrea Recordati has repeatedly described urology as one of the group’s core therapeutic pillars alongside rare diseases and cardiovascular treatments. Silodosin products, including Silodosin Recordati, sit in the mature prescription segment that generates ongoing cash flow to support investment in newer specialty medicines. The company promotes the brand mainly to urologists and general practitioners rather than directly to consumers, with a focus on clear diagnostic criteria and long-term management of benign prostatic hyperplasia.

In markets such as Italy and other EU countries, Silodosin Recordati competes with other silodosin generics and with alternative ?-blockers like tamsulosin, as well as 5?-reductase inhibitors that target prostate volume. Pricing is generally handled within national reimbursement systems rather than as an out-of-pocket consumer decision, which means many patients experience the product simply as one reimbursed box among several BPH options on the pharmacy counter.

Market presence and availability

Silodosin Recordati is authorised in the European Union via national procedures, rather than a centralised EU authorisation, and is typically marketed in Italy and selected European markets under the Recordati brand. Availability and reimbursement conditions vary by country, with some health systems requiring prior specialist diagnosis or specific symptom thresholds before covering the drug. In Germany, silodosin is present mainly through other brands and generics, so Silodosin Recordati itself is not as visible as in the company’s home market.

The product is prescription-only and is not sold on consumer platforms such as amazon.de, which is typical for prescription urology medicines in Europe. For investors, that means sales data for Silodosin Recordati show up only at an aggregated portfolio level in Recordati’s reporting, not as a separate retail trend that can be tracked through online rankings.

Context for Recordati shares

Silodosin Recordati illustrates how the Italian group continues to lean on established, cash-generating primary-care and urology brands while expanding in rare diseases. These steady prescription products help smooth the earnings profile alongside more volatile specialty launches. Recordati shares are listed on the Italian stock exchange in Milan under ISIN IT0003828271.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.